Esophagogastric Junction (EGJ)
1 clinical trials · Condition
◉ Watch Esophagogastric Junction (EGJ)
| Record | Firm | Date |
|---|---|---|
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859) | USWM CT, LLC | 2019-08-20 |
Track Esophagogastric Junction (EGJ) automatically
Every clearance here is in the API, with alerts when new ones post.